Background {#Sec1}
==========

With an incidence of 5.25 per 100,000 \[[@CR1]\] gastroenteropancreatic neuroendocrine tumours (GEP-NET) are a relatively rare disease. They are usually slow-growing and often do not produce clear symptoms until they are metastasised. Currently, surgical tumour resection is the only curative treatment, and usually only in patients with localised disease \[[@CR1]--[@CR4]\]. The primary aims of available therapeutic options are to provide symptom relief, control tumour growth, improve long-term survival, and, not least, preserve psychosocial well-being and health-related quality of life (HRQoL) \[[@CR2], [@CR4]\].

The past two decades have shown that the patient's subjective perspective on his/her own health, quality of life, and treatment-related aspects plays an essential role in treatment evaluation. Traditional physician proxy ratings on morbidity correlate only poorly with several self-reported functional capacity and well-being domains \[[@CR5]\] -- areas which are of utmost importance for the individual patient in managing his/her everyday life with the disease. These aspects are represented in the concept of HRQoL. There is agreement that HRQoL describes "the extent to which one's usual or expected physical, emotional, and social well-being is affected by a medical condition or its treatment" (\[[@CR6]\], p. 73) and needs to be assessed as a patient-reported outcome (PRO). PROs comprise any self-report of a patient's health status without interpretation by a third person \[[@CR7]\].

The assessment of HRQoL as an important secondary outcome in clinical studies, using reliable and valid self-report instruments, has become the criterion standard in oncology \[[@CR8]--[@CR10]\]. To date, systematic assessments of HRQoL in patients with GEP-NET have hardly been performed. High-quality information on HRQoL serves a variety of purposes, from the development of targeted interventions to informed decision making about treatment options to the allocation of healthcare resources \[[@CR11]\].

Based on the assumptions above, we conducted a systematic review on studies incorporating HRQoL in patients with GEP-NET to evaluate the methodological quality of HRQoL processing and reporting. In detail, this review aims at investigating (i) the amount of available information on HRQoL in patients with GEP-NET, (ii) how HRQoL was assessed and reported, and (iii) if the quality of HRQoL information provided meets agreed standards.

Methods {#Sec2}
=======

We applied a systematic approach to identify and appraise studies on HRQoL in GEP-NET patients. Criteria for the selection, description and evaluation of studies were based on the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) checklist \[[@CR12]\], the Cochrane Consumers and Communication Review Group's Extraction Template \[[@CR13]\], and the Minimum Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials \[[@CR14]\].

Search strategy {#Sec3}
---------------

A systematic literature search was conducted in September 2014 and updated in July 2016 using PubMed, EMBASE, and CENTRAL. We searched for original research articles published in English, Italian, French, or German and restricted the search to studies on humans. Combinations of the following MeSH and free text terms were used: neuroendocrine tumors, digestive system neoplasms, neuroendocrine, endocrine, NET, foregut, midgut, hindgut, quality of life, patient-reported, self-reported, well-being, psycho\*. An exemplary search history for PubMed is provided in [Appendix](#Sec14){ref-type="sec"}.

In addition, we also searched OpenGrey ([http://www.opengrey.eu](http://www.opengrey.eu/)) and BIOSIS previews (<http://www.dimdi.de/static/de/db/dbinfo/ba70.htm>) for the identification of grey literature. Database searches were augmented by a manual search of reference lists of included articles to identify further eligible studies not detected by our search terms.

Inclusion criteria and data extraction {#Sec4}
--------------------------------------

Due to the scarceness of studies on the topic of HRQoL in patients with GEP-NET, it was decided not to impose restriction criteria concerning study design in order to comprehensively capture the available information. Any study with a quantitative approach assessing self-reported HRQoL was considered eligible. Publications that were letters, editorials, narrative reviews, and case reports were excluded. Methodological studies on HRQoL in this patient group (e.g., instrument development) were considered not eligible. A data collection form was based on the Cochrane Consumers and Communication Review Group's Extraction Template, adapted to study requirements, pilot tested on five randomly selected reports and refined accordingly.

Eligibility assessment and data extraction were performed by two independent researchers. In the case of disagreement, a third reviewer was consulted to reach final consensus. For the assessment of interrater agreement a simple Kappa calculation was performed, with values between .61 and .80 indicating substantial and of \> .81 almost perfect agreement \[[@CR15]\].

Study evaluation {#Sec5}
----------------

For study evaluation we adapted the Minimum Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials \[[@CR14]\] and the Consolidated Standards of Reporting Trials (CONSORT) PRO extension checklist \[[@CR16]\] for our requirements (i.e., applicable to a range of different study designs in addition to randomised controlled trials (RCTs)). Multiple reports on the same study were linked together and were subsequently defined as one study.

Quality criteria were defined according to study design {#Sec6}
-------------------------------------------------------

For all studies it was documented if:HRQoL was identified as primary or secondary outcome in the abstract (for studies with more than one outcome parameter),there was an a priori hypothesis concerning HRQoL (not applicable if explorative),an explicit rationale for HRQoL instrument selection was provided,the instrument was validated or psychometric properties were reported or referenced,the HRQoL instrument was cancer-specific,the instrument administration was reported,missing data was documented or discussed,statistical considerations for dealing with missing data were provided,reports on HRQoL results were complete and scoring was correct,the issue of clinical significance had been addressed.

For cross-sectional studies it was additionally documented if:compliance was reported.

For all kinds of prospective studies it was additionally documented if:baseline compliance was documented,the timing of assessment was reported.

For prospective and comparative studies it was additionally documented if:statistical power or effect sizes for HRQoL results were reported.

For studies with HRQoL as secondary outcome it was additionally documented if:HRQoL results were considered in [discussion](#Sec12){ref-type="sec"} section.

Results {#Sec7}
=======

Study selection and study characteristics {#Sec8}
-----------------------------------------

The literature search yielded a total of 1506 records (after removing duplicates). Figure [1](#Fig1){ref-type="fig"} shows the flow-diagram of the selection process. We screened titles and abstracts and excluded 88 case-reports and non-original research reports such as comments and letters. Subsequently, 791 studies were excluded for not investigating GEP-NET, and 566 were excluded for not investigating HRQoL. Grey literature search yielded five conference abstracts reporting on studies dealing with HRQoL issues which were not (or not yet) published as full reports and, therefore, not included in the review. Four additional studies were identified by hand search of reference lists of relevant articles. After these selection steps, 65 potentially relevant full-text articles remained and were assessed for eligibility. Out of these, 14 articles were excluded from the review for the following reasons: ten did not measure self-reported HRQoL (e.g., used the Karnofsky Performance Score), and four were methodological studies either on HRQoL instrument development or comparison of instruments. With a Kappa of .818 (*p* ≤ .001) the level of agreement between the two reviewers concerning inclusion or exclusion of a full-text article assessed for eligibility was high.Fig. 1Flow-diagram of study selection process

In total, 51 articles, which reported on 48 separate studies, were included. Eight were RCTs which assessed HRQoL as a secondary outcome to the primary endpoints response, progression-free survival, or time to progression. Additionally, 25 prospective studies, including 15 phase II trials, and 15 observational cross-sectional studies were identified.

Sample sizes ranged between 9 and 663 patients with a median of 51. Most of the studies investigated patients in an advanced stage of disease and administered the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) for assessing HRQoL. In total, 22 studies used either HRQoL or another PRO (e.g., fear of recurrence) as a primary outcome measure. Eight studies compared HRQoL scores with normative values from the national general population. For details on study characteristics see Table [1](#Tab1){ref-type="table"}.Table 1Study characteristics of identified studiesAuthor, yearSample size, diagnosis (disease severity)Treatment modality/interventionComparisonPRO primary outcomeHRQoL measureRandomised controlled trialsArnold et al., 2005 \[[@CR52]\]*N* = 109, foregut, midgut NET, CUP (locally advanced, metastatic)octreotideoctreotide + INTnoQLQ-C30Bajetta et al., 2006 \[[@CR53]\]*N* = 60, well-differentiated intestinal, pancreatic, bronchial NET, other, CUP (low-grade malignancy)lan ATGlan MPnoQLQ-C30Caplin et al., 2014 \[[@CR42]\] *(CLARINET)N* = 204, well- or moderately differentiated pancreatic, midgut, hindgut NET, other, CUP (progressive, metastatic)lan ATGplacebonoQLQ-C30, QLQ-GI.NET21Jacobsen & Hanssen, 1995 \[[@CR54]\]*N* = 11, intestinal NET, PNET (liver metastases)octreotideplacebo (cross-over design)noGHQ-30, PAISMeyer et al., 2014 \[[@CR55]\]*N* = 86, PNET, GI foregut NET, CUP (advanced, metastatic)capecitabine + streptozocin + cisplatinecapecitabine + streptozocinnoQLQ-C30Raymond et al., 2011 \[[@CR56]\]*N* = 171, well-differentiated PNET (advanced, metastatic)sunitinibplacebonoQLQ-C30Rinke et al., 2009 \[[@CR57]\] *(PROMID)N* = 85, well-differentiated midgut NET (metastatic)octreotide LARplacebonoQLQ-C30Yao et al., 2016 \[[@CR45]\] *(RADIANT-4)N* = 302, well-differentiated GI-NET, bronchopulmonary NET (advanced, progressive)everolimusplacebonoFACT-GPhase II studiesBodei et al., 2011 \[[@CR58]\]*N* = 51, bronchial, pancreatic, duodenal, ileal, appendicular, sigma-rectal NET, CUP (progressive, other)^177^Lu-DOTATATE-noQLQ-C30Bushnell et al., 2010 \[[@CR59]\]*N* = 90, carcinoid (metastatic, refractory to octreotide)^90^Y-DOTADOC-noEQ-5DClaringbold et al., 2011 \[[@CR60]\]*N* = 33, well-differentiated NET (progressive)^177^Lu-DOTATATE-noQLQ-C30Cwikla et al., 2010 \[[@CR61]\]*N* = 60, GEP-NET (progressive, metastatic)^90^Y-DOTATATE-noQLQ-C30, QLQ-GI.NET21Delpassand et al., 2014 \[[@CR62]\]*N* = 37, GEP-NET (progressive)^177^Lu-DOTATATE-noQLQ-C30Ducreux et al., 2014 \[[@CR43]\];\
Mitry et al., 2014 \[[@CR44]\] *(BETTER)N* = 34, well-differentiated PNET (progressive, metastatic)\
*N* = 49, well-differentiated GI-NET (progressive, metastatic)bevacizumab + 5-FU/streptozocin;\
bevacizumab + capecitabine-noQLQ-C30Frilling et al., 2006 \[[@CR63]\]*N* = 18, ileal, pancreatic NET, paraganglioma, gastrinoma, CUP (progressive, metastatic)^90^Y-DOTATOC; ^177^Lu-DOTATOC-noSF-36Khan et al., 2011 \[[@CR64]\]*N* = 256, carcinoid, PNET, CUP, gastrinoma, glucagonoma, insulinoma, VIPoma (with and without metastases)^177^Lu-DOTATATE-yesQLQ-C30Korse et al., 2009 \[[@CR65]\]*N* = 39, GI-NET (advanced, metastatic)octreotide LAR-noQLQ-C30Kulke et al., 2008 \[[@CR66]\]*N* = 107, carcinoid, PNET (advanced)sunitinib-noEQ-5D, FACIT-Fatigue scaleKvols et al., 2012 \[[@CR67]\]*N* = 45, GI-NET (advanced, metastatic)pasireotide-noFACIT-DMartin-Richard et al., 2013 \[[@CR68]\]*N* = 30, well-differentiated GEP-NET, bronchopulmonary NET, CUP (progressive)lan ATG-noQLQ-C30Ruszniewski et al., 2004 \[[@CR69]\]*N* = 71, foregut, midgut, hindgut NET, other (not terminally ill)lan PR-noQLQ-C30Wymenga et al., 1999 \[[@CR70]\]*N* = 55, carcinoid, gastrinoma, VIPoma (tumour stages III and IV)lan PR-noQLQ-C30Zuetenhorst et al., 2004 \[[@CR71]\]*N* = 26, well-differentiated ileo-cecal, gastric, bronchopulmonary NET, CUP (metastatic)INT followed by unlabelled MIBG followed by ^131^I-MIBG-noQLQ-C30Prospective studiesFröjd et al., 2007 \[[@CR72]\];\
Fröjd et al., 2009 \[[@CR73]\]*N* = 36, carcinoid (metastatic, other)INT; octreotide; INT + octreotide; CTX; octreotide + CTX; no treatmentnormative data (subsample)yesQLQ-C30Haugland et al., 2013 \[[@CR74]\]*N* = 37, GI-NET (not terminally ill)medical treatment (n.s.)-yesSF-36Kalinowski et al., 2009 \[[@CR75]\]*N* = 9, bronchial, jejunal, ileal, gastric NET, PNET, insulinoma (liver metastases)^90^Y microspheres-noQLQ-C30, QLQ-LMC21Kwekkeboom et al., 2003 \[[@CR76]\]*N* = 35, GEP-NET (progressive, other)^177^Lu-DOTATATE-noQLQ-C30Larsson & Janson, 2008 \[[@CR77]\]*N* = 18, midgut carcinoid (n.s.)INT-yesQLQ-C30, FACT-AnLarsson et al., 2001 \[[@CR78]\]*N* = 24, midgut carcinoid (metastatic, other)INT; SSA; INT + SSAnormative datayesQLQ-C30O'Toole et al., 2000 \[[@CR79]\]*N* = 33, intestinal NET, PNET, other (metastatic)octreotide followed by lanreotidelanreotide followed by octreotidenoISPNPasieka et al., 2004 \[[@CR80]\]*N* = 24, small bowel carcinoid, medullary thyroid cancer, CUP (progressive, metastatic)^131^I-MIBG; ^111^In-octreotide-noad hoc questionnaireSpolverato et al., 2015 \[[@CR81]\]*N* = 85, intestinal, pancreatic, bronchial NET, CUP (neuroendocrine liver metastasis)surgical vs. nonsurgical treatment-yesself-constructed questionnaireTeunissen et al., 2004 \[[@CR82]\]*N* = 50, carcinoid, PNET, CUP, gastrinoma, insulinoma (metastatic)^177^Lu-DOTATATE-yesQLQ-C30Cross-sectional studiesBeaumont et al., 2012 \[[@CR83]\];*N* = 663, carcinoid, islet cell, "do not know or not sure which type" (local, regional, distant, currently not present)surgery; surgery + SSA; other; no past/current treatmentnormative datayesSF-36, PROMIS global health short form, PROMIS-29Pearman et al., 2016 \[[@CR84]\]-Gelhorn et al., 2016 \[[@CR85]\]*N* = 11, midgut, hindgut NET (metastatic)telotristat etipratenormative datayesQLQ-C30, QLQ-GI.NET21Haugland et al., 2009 \[[@CR86]\]*N* = 96, GI-NET (not terminally ill)INT; SSA; INT + SSA; CTX; no treatmentnormative datayesSF-36Haugland et al., 2016 \[[@CR87]\]*N* = 196, GI-NET (not terminally ill)medical treatment (n.s.)normative datayesSF-36Larsson et al., 1998 \[[@CR88]\]*N* = 17, carcinoid, PNET (not terminally ill) (+ staff, *N* = 17)INT; SSA; INT + SSA-yesQLQ-C30Larsson, Sjöden et al., 1999 \[[@CR89]\]*N* = 119, carcinoid, PNET (n.s.)INT + octreotid; INT; octreotide; CTX; XTR; omeprazol; no treatment-yesQLQ-C30Larsson, von Essen et al., 1999 \[[@CR90]\]*N* = 99, carcinoid, PNET (not terminally ill)INT; SSA; INT + SSA-yesQLQ-C30Larsson et al., 2003 \[[@CR91]\]*N* = 19, carcinoid (n.s.) (+ staff, *N* = 19)INT; SSA; INT + SSA-yessemi-structured interviewsLarsson et al., 2007 \[[@CR92]\]*N* = 83, carcinoid, PNET (n.s.)INT/octreotide; CTX; XTR; omeprazol; no treatment-yesQLQ-C30Petzel et al., 2012 \[[@CR93]\]*N* = 240, PNET, periampullary neoplasms (disease-free after surgery)no current treatment-yesFACT-HepPezzilli et al., 2009 \[[@CR94]\]*N* = 44 PNET (disease free, advanced)SSA; SSA + other; no treatmentnormative datayesSF-12, GHQ-12Pezzilli et al., 2010 \[[@CR95]\]*N* = 44 ileal NET (disease free, advanced)SSA; INT; CTX; SSA + other; no treatmentyesSF-12Ruszniewski et al., 2016 \[[@CR96]\] *(SYMNET)N* = 273, small bowel carcinoid, appendicular, colonic, bronchopulmonary NET, CUP (92 % with metastases)lan ATG-yesQLQ-C30, QLQ-GI.NETvan der Horst-Schrivers et al., 2009 \[[@CR97]\]*N* = 43, midgut NET (metastatic)SSA; INT; SSA + INTnormative datayesQLQ-C30von Essen et al., 2002 \[[@CR98]\]*N* = 85, GI-NET (n.s.)INT; SSA; INT + SSA-yesQLQ-C30Grey literatureGarcia-Hernandez et al., 2012 \[[@CR99]\]*N* = 74, GI-NET (n.a.)n.a.-yesQLQ-C30, QLQ-GI.NET21Gyökeres et al., 2010 \[[@CR100]\]*N* = 93, GI-NET (59 % with metastases)SSA-yesQLQ-C30, QLQ-GI.NET21Marinova et al., 2016 \[[@CR101]\]*N* = 68, PNET (n.a.)PRRT (n.s.)-yesQLQ-C30Pavel et al., 2013 \[[@CR102]\]*N* = 126, PNET (advanced)everolimus-noQLQ-C30, QLQ-GI.NET21Strosberg et al., 2015 \[[@CR103]\]*N* = 230, midgut NET (advanced, progressive, metastatic)^177^Lu-DOTATATEoctreotide LARnoQLQ-C30, QLQ-GI.NET21Note. *CUP* cancer with unknown primary, *CTX* chemotherapy, *GEP-NET* gastroenteropancreatic NET, *GI-NET* gastrointestinal NET, *INT* interferon-α, *lan ATG* lanreotide autogel, *lan MP* lanreotide microparticles, *lan PR* lanreotide prolonged-release, *MIBG* meta-iodbenzylguanidin, *NET* neuroendocrine tumours, *n.a.* not available, *n.s.* not specified, *octreotide LAR* octreotide long-acting repeatable, *PNET* pancreatic NET, *XTR* radiotherapy, *SSA* somatostatin analogues

Applied instruments for measuring health-related quality of life {#Sec9}
----------------------------------------------------------------

The majority of the reviewed studies (31/48) used the EORTC QLQ-C30 \[[@CR17]\], which is one of the most widely used HRQoL questionnaire in oncology in Europe. It has been shown to have good validity and reliability and consists of 30 items incorporating five functional scales (physical, role, emotional, cognitive, social), three symptom scales (fatigue, nausea/vomiting, pain), six single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties) and one scale assessing global health status/QoL. Scores are linearly transformed to a 0--100 scale with higher scores representing a higher level of functioning and a higher level of symptomatology, respectively. As defined by Osoba et al. \[[@CR18]\], mean changes in HRQoL scores over time of 5 to 10 points are considered as "small", 10 to 20 points as "moderate", and more than 20 points as "large" with regard to clinical relevance. The QLQ-C30 can be supplemented with disease- and treatment-specific modules. The NET-specific module, the QLQ-GI.NET21 \[[@CR19]\], was used in four of the reviewed studies. It covers issues specific for GEP-NET and is applicable to patients suffering from endocrine or gastrointestinal symptoms. One study used the QLQ-LMC21, which is a module for patients with liver metastases from a colorectal tumour.

The same principle of adding disease- and treatment-specific modules to a generic questionnaire is applied by the Functional Assessment of Chronic Illness Therapy (FACIT) measures, which is one of the most frequently used HRQoL measurement systems in the US and Canada. The core questionnaire, the Functional Assessment of Cancer Therapy-General (FACT-G) \[[@CR20]\], is composed of 27 items assessing physical, emotional, functional and social well-being. The FACT-G was used in five studies; applied modules were the FACT-Hepatobiliary, the FACT-Anemia, the FACIT-Diarrhea, and the FACIT-Fatigue.

One study used the Patient-Reported Outcome Measurement Information System 29-item Health Profile (PROMIS-29) which measures HRQoL in seven domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, ability to participate in social roles and activities) and was designed for patients with a wide range of chronic diseases \[[@CR21]\]. In another study the Psychosocial Adjustment to Illness Scale (PAIS) was used. The PAIS was designed as a semi-structured clinical interview assessing a patient's psychosocial adjustment to medical illness in terms of multiple domains (health care orientation, vocational environment, domestic environment, sexual relationships, extended family relationships, social environment, psychological distress) \[[@CR22]\].

Generic instruments, namely the 36-Item Short Form Health Survey (SF-36), the 12-Item Short Form Health Survey (SF-12), the Euroqol-5 Dimension (EQ-5D), the General Health Questionnaire 30 (GHQ-30) and 12 (GHQ-12), and the French version of the Nottingham Health Profile (ISPN), were used in 10 studies. These instruments assess physical, emotional, functional and social aspects that are applicable across patient groups and diseases and are therefore less suitable for the identification of cancer site- or problem-specific concerns \[[@CR23]\].

Evaluation of methodological quality of HRQoL reporting {#Sec10}
-------------------------------------------------------

Detailed information for each study based on the Minimum Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials and the CONSORT PRO extension checklist is provided in Table [2](#Tab2){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} shows the percentage of studies meeting the CONSORT PRO reporting criteria. The percentage of studies meeting additional quality criteria is depicted in Fig. [3](#Fig3){ref-type="fig"}. It should be noted that stated percentages do not always refer to all 48 extracted studies, but to the total number of studies that met the defined criteria.Table 2Study evaluation according to defined quality criteriaAuthor, yearHRQoL stated as prim./sec. aim^a^A priori hypothesisInstrument rationalInstrument validation^b^Cancer-specific instrumentInstrument administration(Baseline) complianceTiming of assessmentsMissing data reportedStatistical methods for missing dataPower or effect sizes (HRQoL)Presentation of results adequate^c^Clinical significance addressedHRQoL results discussedRandomised controlled trialsArnold et al., 2005 \[[@CR52]\]\--+++-+++\-\-\--+Bajetta et al., 2006 \[[@CR53]\]\-\--+++-+++\-\--+Caplin et al., 2014 \[[@CR42]\] *(CLARINET)*+\--++\--+++-+\--Jacobsen & Hanssen, 1995 \[[@CR54]\]+\--+-^d^-+++\-\--++Meyer et al., 2014 \[[@CR55]\]+\--++-+++\-\-\-\--Raymond et al., 2011 \[[@CR56]\]\-\--+++-++\-\--++Rinke et al., 2009 \[[@CR57]\] *(PROMID)*\-\--++-++\-\-\-\-\--Yao et al., 2016 \[[@CR45]\] *(RADIANT-4)*\--++++++-+-n.r.+n.r.Phase II studiesBodei et al., 2011 \[[@CR58]\]\-\--++\--+\-\-\-\--+Bushnell et al., 2010 \[[@CR59]\]\-\--+\--+++\-\-\-\--Claringbold et al., 2011 \[[@CR60]\]\-\--++\--++\-\-\--+Cwikla et al., 2010 \[[@CR61]\]\-\--+++-++\-\-\-\--Delpassand et al., 2014 \[[@CR62]\]\-\--++\--++\-\-\-\--Ducreux et al., 2014 \[[@CR43]\];\
Mitry et al., 2014 \[[@CR44]\] *(BETTER)*+\--++\--++\-\-\-\--Frilling et al., 2006 \[[@CR63]\]\-\--+\-\--++\-\-\-\--Khan et al., 2011 \[[@CR64]\]N/A-+++++++\-\--++Korse et al., 2009 \[[@CR65]\]N/A-+++^d^\-\--+\-\-\--N/AKulke et al., 2008 \[[@CR66]\]\-\--+-+-++\-\-\--+Kvols et al., 2012 \[[@CR67]\]\-\--++\--++\-\-\--+Martin-Richard et al., 2013 \[[@CR68]\]+\--++\--+\-\--+\--Ruszniewski et al., 2004 \[[@CR69]\]\-\--++-+++\-\-\--+Wymenga et al., 1999 \[[@CR70]\]\-\--++\--+-+-+-+Zuetenhorst et al., 2004 \[[@CR71]\]-+-++^d^\--++\-\-\--+Prospective studiesFröjd et al., 2007 \[[@CR72]\];\
Fröjd et al., 2009 \[[@CR73]\]N/AN/A-++^d^+++++-++N/AHaugland et al., 2013 \[[@CR74]\]N/A\--+-+++++++-N/AKalinowski et al., 2009 \[[@CR75]\]\--+++\--+\-\-\-\--+Kwekkeboom et al., 2003 \[[@CR76]\]\-\--+++-++\-\-\--+Larsson & Janson, 2008 \[[@CR77]\]N/AN/A+++\--++\--++N/ALarsson et al., 2001 \[[@CR78]\]N/A\--++^d^++++\--++N/AO'Toole et al., 2000 \[[@CR79]\]-+-+-^d^+-+\-\--+-+Pasieka et al., 2004 \[[@CR80]\]\-\-\-\--++++\-\--++Spolverato et al., 2015 \[[@CR81]\]N/A++-+++++\-\-\--N/ATeunissen et al., 2004 \[[@CR82]\]N/AN/A++++-+++-++N/ACross-sectional studiesBeaumont et al., 2012 \[[@CR83]\];N/AN/A-+-++N/A+-+++N/APearman et al., 2016 \[[@CR84]\]-Gelhorn et al., 2016 \[[@CR85]\]-N/A-++++N/A+-N/A-++Haugland et al., 2009 \[[@CR86]\]N/AN/A++-++N/A+-+++N/AHaugland et al., 2016 \[[@CR87]\]N/A+-+-++N/A++\-\--N/ALarsson et al., 1998 \[[@CR88]\]N/AN/A+++^d^++N/A+-N/A\--N/ALarsson, Sjöden et al., 1999 \[[@CR89]\]N/AN/A++++-N/A+-N/A++N/ALarsson, von Essen et al., 1999 \[[@CR90]\]N/AN/A+++^d^++N/A+-N/A++N/ALarsson et al., 2003 \[[@CR91]\]N/AN/AN/AN/AN/A+-N/A+N/AN/AN/AN/AN/ALarsson et al., 2007 \[[@CR92]\]N/AN/A+++^d^++N/A+-N/A+-N/APetzel et al., 2012 \[[@CR93]\]N/A+++++-N/A++N/A+-N/APezzilli et al., 2009 \[[@CR94]\]N/A\--+-++N/A+\-\-\--N/APezzilli et al., 2010 \[[@CR95]\]N/A\--+-+-N/A\-\-\-\--N/ARuszniewski et al., 2016 \[[@CR96]\] *(SYMNET)*-N/A-+++-N/A-++\--+van der Horst-Schrivers et al., 2009 \[[@CR97]\]N/AN/A-++++N/A\-\--+-N/Avon Essen et al., 2002 \[[@CR98]\]N/AN/A-++++N/A+\-\-\--N/ANote. ^a^in the abstract of the article; ^b^or psychometric properties reported; ^c^considered adequate if scoring has been performed correctly and if all assessed HRQoL domains were reported (including relevant *p*-values); ^d^additional ad hoc questions on symptoms added; *N/A* not applicable due to study design, *n.r.* not reportedFig. 2Percentage of studies meeting CONSORT PRO extension criteriaFig. 3Percentage of studies meeting additional quality criteria from HRQoL checklist

Study evaluation revealed three major topics of concern. The first is a lack of knowledge on how to assess and process HRQoL data, and here particularly the absence of a priori hypotheses on HRQoL outcomes in 85 % and missing rationales for applied questionnaires in 70 % of studies. The second is a lack of adequate reporting of HRQoL results. For 65 % of studies, the presentation of results was rated inadequate, either due to incomplete reporting of HRQoL scores (only single scales or statistical significant results) or due to invalid score calculation (i.e., not according to the respective scoring manual). The third is related to the statistical methods as well as interpretation and discussion of HRQoL results. Information on the handling of missing data was not given in 79 % of studies. Less than one third of the studies (30 %) addressed the issue of clinical significance of findings. Further evaluation revealed that studies which investigated HRQoL as a primary outcome showed higher methodological quality of HRQoL data than those that included HRQoL as a secondary outcome measure. This was especially true for presentation and interpretation of results.

Overview on HRQoL outcomes {#Sec11}
--------------------------

From our literature search, we identified 8 RCTs investigating a broad range of patient groups regarding cancer site and stage, disease duration, as well as treatment modality. According to the predefined criteria, reporting of HRQoL data was of moderate to poor quality, especially in terms of completeness and adequate presentation of results. Thus, due to heterogeneity and methodological limitations of studies, no firm conclusions for clinical practice can be drawn.

There is evidence from non-RCTs including HRQoL as a primary outcome that patients with GEP-NET perceive their overall HRQoL as relatively good and stable. However, in-depth evaluation of these studies revealed a range of physical and psychosocial complaints primarily related to diarrhoea, flushing, and fatigue, as well as emotional, social, and role functioning when compared to the general population. Again, it has to be noted that these results should be interpreted with caution and not be considered as a basis for informing clinical practice and decision making. A brief summary of primary outcomes and HRQoL results of the reviewed studies is provided in Additional file [1](#MOESM1){ref-type="media"}.

Discussion {#Sec12}
==========

The evaluation of HRQoL in patients with GEP-NET has attracted increasing interest in recent years. Despite this positive trend, however, there is still little knowledge available on this topic, and existing studies have major methodological limitations that hinder the application of HRQoL findings in daily clinical practice. The aim of this review was to evaluate the methodological quality of studies on HRQoL in GEP-NET patients, from data collection through to interpretation of results.

Our literature search yielded 58 abstracts ostensibly dealing with HRQoL issues in GEP-NET patients. However, further evaluation reveals that ten of these studies did not assess HRQoL at all but rather performed proxy ratings on physical functioning and self-care abilities. As the agreed definition of HRQoL is that it assesses a range of health issues beyond physical abilities and inevitably comprises patients' self-reports \[[@CR7], [@CR24]--[@CR26]\], these studies were excluded from the systematic review.

The evaluation of the remaining 48 studies, on a positive note, revealed a consistent application of appropriate HRQoL instruments. The majority of studies (35/48) used a cancer-specific questionnaire with already proven reliability and validity. This finding is in line with previous studies on the quality of PRO reporting in oncology RCTs, indicating that a majority of studies including PROs used validated disease- or at least cancer-specific instruments \[[@CR27]--[@CR29]\]. In the current review, nine studies amended these questionnaires with ad hoc questions on NET-specific symptoms, such as diarrhoea and hot flushes. It should be noted, however, that this was done in the absence of validated NET-specific PRO instruments. One study, however, administered an ad hoc instrument alone (i.e., not in combination with another validated measure) and another study used a self-constructed questionnaire comprising elements of validated measures. The term 'ad hoc' refers to the fact that these questions were not formally developed and had not undergone psychometric testing. In order to ensure high methodological quality and improve comparability of data across different studies, ad hoc questions should be considered only, if there are no appropriate validated PRO instruments \[[@CR30], [@CR31]\]. There is awareness of the fact that novel treatment agents may entail a range of symptoms not currently covered by validated PRO/HRQoL instruments \[[@CR32]--[@CR34]\] and methodological approaches of addressing this issue are being discussed. The EORTC Quality of Life Group (QLG) runs a database with an item pool including all questions from the disease-specific supplementary modules of the QLQ-C30, validated for cancer patients and different languages. Selecting suitable questions from such an item bank should be preferred over designing ad hoc questions. For patients with GEP-NET, two disease-specific questionnaires, the EORTC QLQ-GI.NET21 \[[@CR19]\], a module to be applied together with the core questionnaire QLQ-C30, and the Norfolk QOL-NET \[[@CR35]\], a NET-specific stand-alone measure, have become available only recently.

A range of methodological shortcomings were identified in assessing and processing as well as in reporting and interpreting HRQoL data. Most of the reviewed studies were heterogeneous in terms of study design and quality making it impossible to draw meaningful conclusions for clinical practice at this point. This refers primarily to studies investigating HRQoL as a secondary outcome. A large percentage of these studies provided only crude or incomplete presentations of HRQoL results or did not apply correct scoring procedures as prescribed by respective manuals. One of the included RCTs used HRQoL as a secondary outcome, as indicated in the clinical trial protocol as well as in the [Methods](#Sec2){ref-type="sec"} section of the respective main publication, but failed to report on these issues both in the [Results](#Sec7){ref-type="sec"} and [Discussion](#Sec12){ref-type="sec"} section. Another common limitation was the lack of information on the statistical approach of handling missing HRQoL data, which was also found in previous reviews including different malignancies such as brain, bladder, prostate, and gynaecological cancers \[[@CR27], [@CR28], [@CR36], [@CR37]\]. These limitations were apparent even in high-evidence studies that are likely to impact on health policy and practice. None of the eight RCTs included in this review could provide HRQoL information in a way that would allow its use for informed decision making and planning future trials. Thus, while acknowledging the need for assessing HRQoL as an important secondary outcome in clinical studies, there seems to be an uncertainty about the processing of the collected data \[[@CR14], [@CR38]--[@CR40]\]. Similar to the results of previous studies investigating the methodological quality of PRO reporting in patients with brain \[[@CR27]\], prostate \[[@CR36]\], and gynaecological \[[@CR28]\] cancers, further problems were related to the interpretation of HRQoL results, especially regarding the clinical significance of HRQoL findings (e.g., changes over time, differences between treatment arms). Studies included in this review that used HRQoL as a primary outcome provided evidence that patients present with impairments in multiple domains such as emotional, role, and social functioning when compared to general population norms. This is in contrast to findings showing that GEP-NET patients generally perceived their HRQoL as relatively good. As mentioned above, to date, existing studies do not allow for firm conclusions and call for further research to elucidate the time course of HRQoL in this patient group.

Two recent review articles \[[@CR29], [@CR39]\] evaluating the methodological quality of PRO reporting in high-evidence studies on different cancer types indicated that the overall level of reporting according to the CONSORT PRO extension criteria was poor. Exceptions were studies assessing HRQoL as a primary outcome and/or presenting a supplementary report on HRQoL issues which showed a better performance. The overall quality of PRO reporting might benefit from increasing familiarity with HRQoL issues and the development of the above mentioned guidelines \[[@CR29], [@CR36], [@CR39]\]. However, in spite of this development, a recent review on the consistency of available PRO-specific guidance has identified a clear lack of respective recommendations for the appropriate implementation of PROs in clinical research \[[@CR41]\]. Although the checklists applied in this review \[[@CR14], [@CR16]\] do not represent an exhaustive set of criteria for high-quality HRQoL assessment for studies including HRQoL either as a primary or secondary outcome, their application both during study planning and reporting would substantially enhance the quality of the assessed data.

Therefore, while agreeing that further guidance is required to make HRQoL assessment more feasible and -- with increasing quality -- accessible for clinical use, we emphasise the need to adhere to already existing quality standards. Important scientific societies that have shaped the field of HRQoL research in oncology over the past two decades, such as the EORTC QLG, the FACIT group and the International Society for Quality of Life Research (ISOQOL), provide a well-informed basis for the application of PROs and should therefore be consulted when considering their incorporation into clinical trials.

In the field of GEP-NET research, there is a growing number of clinical trials considering HRQoL as an outcome measure \[[@CR42]--[@CR48]\]. However, two recent, not yet published, phase III trials fail to incorporate PRO or HRQoL assessments, as indicated in the respective study protocols \[[@CR49], [@CR50]\]. Furthermore, the methodological quality of information derived thus far is not satisfactory. Considering the fact that such studies have the potential to impact on health policy and practice, the importance of generating high-quality HRQoL data cannot be overstated. Poorly designed and/or reported PROs are likely to undermine the credibility of the results, which in turn hinders their application in daily clinical practice \[[@CR9], [@CR14], [@CR27], [@CR29], [@CR37], [@CR39], [@CR40]\]. Especially with the movement towards a more patient-centred health care system, the incorporation of the patient's subjective perspective plays a pivotal role in facilitating patient involvement in health care, thereby enhancing patient empowerment and satisfaction \[[@CR51]\].

Conclusions {#Sec13}
===========

Despite an increasing interest in assessing HRQoL in patients with GEP-NET, there is still little knowledge on the course of HRQoL over time, highlighting the need for high-quality longitudinal studies. Existing studies show methodological shortcomings in both processing and reporting of HRQoL data, especially when included as a secondary outcome in clinical trials. Methodological limitations were identified even for studies with high evidence level, which is considered problematic given their impact on health policy and medical practice. Thus, the valid application of HRQoL findings in clinical practice is hampered not only by lack of studies, but also by various methodological limitations of the existing ones. High-quality, well-reported HRQoL data is of utmost importance to make results accessible and useful to patients and their treating physicians. Therefore, it is strongly recommended to adhere to existing guidelines on the incorporation of PROs into clinical research.

Appendix {#Sec14}
========

Table 3Exemplary search history for PubMedSearchAdd to builderQueryItems found\#16AddSearch (((((((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported))) NOT ((review) OR case-report))) NOT (((melanoma) OR schwannoma) OR ac\*ustic neuroma) Filters: Classical Article; Clinical Study; Clinical Trial; Comparative Study; Controlled Clinical Trial; Multicenter Study; Observational Study; Randomized Controlled Trial; Humans; English; French; German; Italian; Spanish796\#15AddSearch (((((((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported))) NOT ((review) OR case-report))) NOT (((melanoma) OR schwannoma) OR ac\*ustic neuroma) Filters: Classical Article; Clinical Study; Clinical Trial; Comparative Study; Controlled Clinical Trial; Multicenter Study; Observational Study; Randomized Controlled Trial; Humans815\#14AddSearch (((((((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported))) NOT ((review) OR case-report))) NOT (((melanoma) OR schwannoma) OR ac\*ustic neuroma) Filters: Classical Article; Clinical Study; Clinical Trial; Comparative Study; Controlled Clinical Trial; Multicenter Study; Observational Study; Randomized Controlled Trial858\#13AddSearch (((((((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported))) NOT ((review) OR case-report))) NOT (((melanoma) OR schwannoma) OR ac\*ustic neuroma)4198\#12AddSearch (((((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported))) NOT ((review) OR case-report)15865\#11AddSearch ((melanoma) OR schwannoma) OR ac\*ustic neuroma132755\#10AddSearch (review) OR case-report4299707\#9AddSearch (((neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))))) AND (((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported)24382\#8AddSearch (neuroendocrine tumor\[MeSH Terms\]) OR ((digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\])))151289\#7AddSearch (digestive system neoplasms\[MeSH Terms\]) AND (((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]))11944\#6AddSearch ((((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\])) OR (((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\])241029\#5AddSearch ((((quality of life) OR psycho\*) OR well-being) OR patient-reported) OR self-reported5592512\#4AddSearch ((foregut\[Title/Abstract\]) OR midgut\[Title/Abstract\]) OR hindgut\[Title/Abstract\]12719\#3AddSearch ((neuroendocrine\[Title/Abstract\]) OR endocrine\[Title/Abstract\]) OR NET\[Title/Abstract\]229180\#2AddSearch digestive system neoplasms\[MeSH Terms\]512405\#1AddSearch neuroendocrine tumor\[MeSH Terms\]145008
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CONSORT

:   Consolidated standards of reporting trials

EORTC

:   European Organisation for research and treatment of cancer

FACIT

:   Functional assessment of chronic illness therapy

GEP-NET

:   Gastroenteropancreatic neuroendocrine tumours

HRQoL

:   Health-related quality of life

ISOQOL

:   International society for quality of life research

Norfolk QOL-NET

:   Norfolk quality of life -- neuroendocrine tumor questionnaire

PRISMA

:   Preferred reporting items of systematic reviews and meta-analyses

PRO

:   Patient-reported outcome

QLG

:   Quality of life group

QLQ-C30

:   Quality of life questionnaire core 30

QLQ-GI.NET21

:   Quality of life questionnaire -- neuroendocrine carcinoid
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